Abstract:Introduction: Cardiovascular diseases have been the leading causes of death all over the world for decades. Vascular smooth muscle cells (VSMCs) form a major section of a blood vessel, conferring structural and physiological support to withstand any change under physiological or pathological conditions. VSMC phenotypic modulation from a contractile phenotype to a synthetic state is pivotal for the development of several vascular diseases such as neointima formation after angioplasty and atherosclerosis. Decreased expression of VSMC differentiation markers including SM ɑ-actin (Acta2), SM-myosin heavy chain (Myh11) and SM22 alpha (Tagln) indicates VSMC phenotypic switching, which is accompanied by increasing VSMC proliferation, migration and synthesis of metalloproteinase[1]. However, the molecular mechanisms that underlie VSMC phenotypic switching remain largely unknown. SMYD2, a SET and MYND domain-containing protein, belongs to the SMYD family of protein lysine methyltransferases. Structurally, SET domain regulates lysine methylation of target proteins (as involved in transcription, cell differentiation and cell proliferation), while zinc finger motif MYND domain may interact with proline rich regions and facilitate protein-protein interaction. SMYD2 was originally reported to methylate histone 3 at lysine 4 (H3K4) and lysine 36 (H3K36) and H4 at lysine 20 (H4K20), and plays an essential role in HIV-1 latency and cardiac development [2-3]. Some studies found that SMYD2 can also methylate non-histone proteins such as p53, Hsp90, and Rb and regulate their functions [4-6]. Interestingly, SMYD2 has recently been implicated in human patients with abdominal aortic aneurysm in GWAS screening [7]. The aim of this study is to investigate the role of SMYD2 in the control of VSMC phenotypic switching and neointima formation. Methods: We used Western blotting and PCR to assess SMYD2 expression and VSMC marker gene expression in VSMC phenotypic change in vitro and murine carotid ligation injury model in vivo. In the ligation injury model, right common carotid artery (CCA) was ligated and harvested after 7, 14, and 28 days. SMYD2smc-/- (SMYD2 conditional knockout in VSMCs) mice and SMYD2flox/flox (SMYD2 flox control) mice were subjected to ligation model and CCA was obtained for histological evaluation after7 days, 14 days and 28days. Primary VSMCs were isolated from SMYD2smc-/- mice and SMYD2flox/flox mice and then VSMC marker gene expression was examined by Western blotting and PCR. Furthermore, we also checked expression of SMYD2 in murine atherosclerosis which is closely related to VSMC phenotypic change. Results: The expression of SMYD2 significantly decreased in response to platelet-derived growth factor BB (PDGF-BB) in the serum-starved VSMCs. In the in vivo model, we found that SMYD2 expression was also reduced in the injured versus sham-operated carotid arteries. In comparison with normal healthy arteries, atherosclerotic arteries have a substantially decreased SMYD2 expression in mouse vascular tissues. Moreover, SMYD2 ablation in VSMCs significantly exacerbated ligation injury-induced neointima formation in mice and drastically inhibited VSMC marker gene expression. Conclusion: Our findings demonstrated that SMYD2 down-regulation in VSMCs promotes VSMC phenotypic changing and neointima formation after injury, suggesting that SMYD2 may function as a novel inhibitor of vascular remodeling associated with physical injury and atherosclerotic disease. Disclosure: Nothing to disclose

Histone Methyltransferase SMYD2: Ubiquitous Regulator of Disease

Setd2, A H3k36 Lysine Methyltransferase, is Essential for Adult Normal Hematopoiesis and Leukemia Stem Cells

SMYD5 Catalyzes Histone H3 Lysine 36 Trimethylation at Promoters

Histone methyltransferase SMYD3 and tumor

Tet2 Activity is Modulated by Sirt1-Mediated Protein Deacetylation: A Potential Therapeutic Target in Myelodysplastic Syndrome

SMYD family in cancer: epigenetic regulation and molecular mechanisms of cancer proliferation, metastasis, and drug resistance

Set and Mynd Domain Containing Protein 3 in Cancer

Regulation of EZH2 by SMYD2-Mediated Lysine Methylation is Implicated in Tumorigenesis.

Structural and Functional Profiling of the Human Histone Methyltransferase SMYD3

Functional Analysis of the Methyltransferase SMYD in the Single-Cell Model Organism Tetrahymena Thermophila

Set and MYND Domain-containing Protein 2 (SMYD2) is a Critical Regulator for Vascular Smooth Muscle Cell Phenotypic Switching and Neointima Formation

The Histone Methyltransferase Smyd2 is a Negative Regulator of Macrophage Activation by Suppressing Interleukin 6 (IL-6) and Tumor Necrosis Factor Α (Tnf-Α) Production.

SMYD2 regulates vascular smooth muscle cell phenotypic switching and intimal hyperplasia via interaction with myocardin

Histone Methyltransferase Smyd2 Drives Vascular Aging by Its Enhancer-Dependent Activity.

The Lysine Methyltransferase SMYD2 Methylates the Kinase Domain of Type II Receptor BMPR2 and Stimulates Bone Morphogenetic Protein Signaling

SMYD5 controls heterochromatin and chromosome integrity during embryonic stem cell differentiation.

SMYD2 targets RIPK1 and restricts TNF-induced apoptosis and necroptosis to support colon tumor growth

SMYD2 Suppresses APC2 Expression to Activate the Wnt/β-catenin Pathway and Promotes Epithelial-Mesenchymal Transition in Colorectal Cancer.

Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase*

The Role Of Histone Methyltransferase Smyd4 In Cardioprogenitor Cell Specification And Differentiation

The role of histone methyltransferase EZH2 in myelodysplastic syndromes.